Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Must have a study partner
    Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    Eligibility Criteria

    Male or female participants aged 55 years of age to 90.
    Must have a study partner
    History of agitation due to AD.

    Recruitment End Date

  • Clinical Trial
    UHN - TO Western - Dr. Tartaglia

    What is this Study about?

    The purpose of this study is to:Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) and Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

    Eligibility Criteria

    Male or female participants aged 40 to 80 years of age
    Has mild cognitive impairment (MCI) or dementia due to AD

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    McMaster University is conducting a study on the effects of brain stimulation in individuals aged 50 and older with dementia or memory loss. The research focuses on using repetitive transcranial magnetic stimulation (rTMS), a noninvasive technique that delivers magnetic pulses to the brain, to enhance cognitive function and balance. The goal is to extend the positive effects of brain stimulation in improving cognition and balance in individuals with dementia.

    Eligibility Criteria

    1.) Diagnosed with Dementia and/or memory loss by a clinician

    2.) Exhibit adequate oral communication skills and cognitive function

    3.) Walk or stand with or without personnel or assistive devices

    4.) Individuals must be greater than or equal to 50 years of age

    Recruitment End Date

  • Observational Study
    In person & Online

    What is this Study about?

    This study explores how adult day programs affect the lives of people living with dementia and their caregivers across several Canadian regions. Over time, we gather information about health, well-being, daily experiences, and quality of life of people living with dementia who attend day program and their caregivers. We also aim to learn about day programs themselves, such as their activities, staffing, challenges, and successes. By combining surveys, interviews, and focus groups, our program of research aims to understand what makes day programs helpful, where challenges exist, and how day program can better support families, and people who use them.

    Eligibility Criteria

    You are eligible to participate if you:

    • Are an older adult living with dementia who attends or does not attend a day program

    • You are a family/friend caregiver of someone living with dementia who attends or does not attend a day program

    • Live in one of the participating regions (Ontario, Winnipeg MB, Calgary AB, or Interior BC)

    • Are able to take part in a conversation or complete surveys, with support if needed

    Recruitment End Date

  • Observational Study
    In person

    What is this Study about?

    This study explores Deep Brain Stimulation (DBS) as a potential treatment for mild Alzheimer’s disease (AD). In this study, the mild electrical stimulation is delivered to a part of the brain called the Pedunculopontine Nucleus (PPN), which helps regulate cognitive and sleep-related brain rhythms. The trial will recruit a small group of participants to evaluate the safety, feasibility, and preliminary efficacy of DBS-PPN in treating AD. The goal of this study is to see if targeting this part of the brain with DBS can help people living with mild AD improve their memory, thinking skills, and sleep quality.

    Eligibility Criteria

    Are 60 years or older
    -Have a diagnosis of mild Alzheimer's Disease
    -Are fluent in English
    -Have a personal caregiver willing to join the study

    Recruitment End Date

  • Observational Study
    In person and online

    What is this Study about?

    This study aims to evaluate the acceptance and usability of the GuardIO Family Care app, a mobile application designed to support community safety for individuals living with dementia or mild cognitive impairment and their care partners. The study also aims to analyze mobility patterns collected from the app to explore how mobility data can contribute to the early detection of cognitive impairment. The findings will help improve app design, inform care strategies, and support early intervention efforts for individuals living with dementia or MCI.

    Eligibility Criteria

    You are eligible to participate if you:

    Are 18 years of age or older

    Are living with mild cognitive impairment (MCI) or dementia, or are a care partner of someone with MCI or dementia

    Are able to use a smartphone or tablet with the GuardIO app

    Are willing to participate in the study activities, including using the app, completing questionnaires, and attending an optional focus group

    Can understand and communicate in English (or another supported language, if applicable)

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    We are conducting three separate studies to explore the effects of transcranial Direct Current Stimulation (tDCS) in individuals with Alzheimer’s Disease or Primary Progressive Aphasia. tDCS is a non-invasive therapy that uses low electrical currents to stimulate specific areas of the brain. Previous research has suggested that tDCS can improve symptoms such as language difficulties and may help slow the progression of Alzheimer’s.

    Our studies aim to investigate these effects in different contexts, including language therapy and overall mental abilities. Upon completion, participants will receive their study results to help guide their decisions about whether tDCS could be part of a long-term therapy plan.

    Eligibility Criteria

    Person living with Alzheimer's disease

    Recruitment End Date

  • Clinical Trial
    Online

    What is this Study about?

    The Communication Bridge 3 Study is focused on helping adults with mild to moderate Primary Progressive Aphasia (PPA), a condition that affects language abilities due to neurodegenerative diseases. The study aims to improve functional communication and life participation by providing structured language and communication support remotely through video conferencing.

    Participants work with speech-language pathologists to practice communication techniques and learn strategies to address daily communication challenges. The study involves a series of therapy sessions, assessments, and follow-up evaluations to measure changes in communication and participation over time. By tracking participants' progress, the study hopes to identify effective approaches for enhancing quality of life for those living with PPA and their care partners.

    Eligibility Criteria

    You are eligible to participate if you speak English as a primary language, a confirmed diagnosis of PPA in mild to moderate impairment stage, a communication partner that is willing to participate, and sufficient internet connection.

    Recruitment End Date